ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 557,36
1,06%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Theratechnologies Inc (THTX)

  7. Theratechnologies Inc (THTX) Actualités

THTX Theratechnologies Inc

1,28
-0,06 (-4,48%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Theratechnologies Inc THTX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,06 -4,48% 1,28 06:00:03
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,31 1,27 1,32 1,28 1,34
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
02/5/202413:30GLOBETheratechnologies to Present Long-Term Efficacy, Safety and..
15/4/202422:15GLOBETheratechnologies Announces Mailing of Management Proxy..
11/4/202413:30GLOBETheratechnologies to Present at the 2024 Bloom Burton & Co...
10/4/202413:30GLOBETheratechnologies Reports Financial Results and Provides..
10/4/202413:15IHMARKETNEWSU.S. Index Futures Show Mixed Trend Ahead of Key Inflation..
08/4/202422:30GLOBETheratechnologies Preclinical Data Presentation at AACR 2024..
05/4/202417:00GLOBETheratechnologies Appoints Elina Tea to its Board of..
03/4/202413:30GLOBETheratechnologies to Announce First Quarter 2024 Financial..
28/3/202412:30GLOBETheratechnologies to Present Preclinical Data at AACR on..
22/3/202414:36GLOBETheratechnologies Announces Update on its Preclinical..
22/3/202401:00GLOBETheratechnologies Appoints Jordan Zwick to its Board of..
21/3/202412:30GLOBETheratechnologies Initiates Increased Dose Level in Phase 1..
29/2/202422:55EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/2/202422:34GLOBETheratechnologies Announces the Resignation of One of Its..
27/2/202414:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/2/202413:30GLOBETheratechnologies Receives Refusal to File Letter for..
21/2/202414:01EDGAR2Form 20-F - Annual and transition report of foreign private..
21/2/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202413:30GLOBETheratechnologies Reports Financial Results for the Fourth..
20/2/202413:30GLOBETheratechnologies Announces Publication in Frontiers in..
15/2/202414:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/2/202413:30GLOBETheratechnologies Completes Enrollment of First Six Patients..
06/2/202420:29EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/2/202413:30GLOBETheratechnologies to Announce Fourth Quarter and Full Year..
01/2/202417:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/1/202419:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/1/202413:00GLOBETheratechnologies Receives Complete Response Letter (CRL)..
23/1/202420:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/1/202413:30GLOBETheratechnologies Receives Update from FDA on Tesamorelin F8..
04/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02/1/202422:28EDGAR2Form F-3/A - Registration statement by foreign private..
02/1/202415:00APSWill This Dual-Listed Bio-Pharma Catch New Year Action?
02/1/202413:30GLOBETheratechnologies Submits sBLA for Trogarzo® Intramuscular..
21/12/202322:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/12/202322:12PRNCATheratechnologies annonce le renouvellement de son..
21/12/202322:09PRNCATheratechnologies Announces Renewal of Shelf Prospectus and..
21/12/202319:21EDGAR2Form F-3 - Registration statement by foreign private issuers
13/12/202320:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/12/202313:30GLOBETheratechnologies Announces FDA Approval of Trogarzo®..
28/11/202322:52EDGAR2Form SC 13D - General statement of acquisition of beneficial..
24/11/202313:30GLOBETheratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation..
06/11/202319:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202318:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/11/202319:26EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202317:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202317:34GLOBETheratechnologies Announces Closing of US$25 Million Public..
27/10/202303:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/10/202315:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/10/202314:00GLOBETheratechnologies Announces Pricing of US$25 Million Public..
25/10/202322:13GLOBETheratechnologies Announces Proposed Public Offering of..

Dernières Valeurs Consultées

NASDAQ
THTX
Theratechnologies
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés